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ABSTRACT 
 
Several adenosine or cytidine deaminase enzymes deaminate transcript sequences in a 
cell type or environment-dependent manner by a programmed process called RNA 
editing. RNA editing enzymes catalyze A>I or C>U transcript alterations and have the 
potential to change protein coding sequences. In this brief review, we highlight some 
recent work which shows aberrant patterns of RNA editing in cancer. Transcriptome 
sequencing studies reveal increased or decreased global RNA editing levels depending on 
the tumor type. Altered RNA editing in cancer cells may provide a selective advantage 
for tumor growth and resistance to apoptosis.  RNA editing may promote cancer by 
dynamically recoding oncogenic genes, regulating oncogenic gene expression by 
noncoding RNA and miRNA editing, or by transcriptome scale changes in RNA editing 
levels which may affect innate immune signaling. Although RNA editing markedly 
increases complexity of the cancer cell transcriptomes, cancer-specific recoding RNA 
editing events have yet to be discovered.  Epitranscriptomic changes by RNA editing in 
cancer represent a novel mechanism contributing to sequence diversity independently of 
DNA mutations. Therefore, RNA editing studies should complement genome sequence 
data to understand the full impact of nucleic acid sequence alterations in cancer.    
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Introduction 
The central dogma of biology refers to the faithful transmission of genetic information 
from DNA to RNA and from RNA to protein. This dogma underlies the rationale to 
examine the genome to understand pathogenesis of human diseases especially cancer. 
Abundant data now show that DNA mutations are fundamental to cancer initiation and 
progression (1). Whereas genetic linkage based approaches in rare cancer-prone families 
have identified many classical tumor suppressor genes, recent high throughput sequence 
analyses of cancer genomes showed somatic mutations driving the neoplastic process (2). 
Recent studies also show that enzymatic alterations in RNA sequences, without any 
corresponding mutation at the DNA level, can also contribute to pathogenesis of cancer 
(3-7).  
 
RNA editing refers to programmed alterations in transcripts catalyzed by adenosine or 
cytidine deaminating enzymes, and benefits the organism by allowing cell-type specific, 
developmentally-regulated or environmentally-induced expression of protein isoforms (8, 
9).  RNA editing alters adenine to inosine (A>I) and cytosine to uracil (C>U) by 
adenosine and cytidine deaminases, respectively. These base transitions at the transcript 
level can lead to missense (by A>I and C>U editing) or nonsense (by C>U editing) 
protein alterations.  Recent sequencing studies highlight that cancer cell transcriptomes 
are more complex than their genomes in part due to widespread RNA editing (4-7). Since 
levels of RNA editing may dynamically change by micro-environmental factors or during 
tumor progression, and that edited transcripts have a limited life span, the functional 
impact of RNA editing on cancer cells will be different than those of permanent DNA 
mutations. Here, we provide a brief overview of the known RNA editing enzymes and 
highlight some recent studies on the role of RNA editing in cancer. 
 
RNA editing by ADARs 
 
A>I RNA editing is catalyzed by the ubiquitously expressed ADAR (ADAR1) and 
ADARB1 (ADAR2) adenosine deaminase enzymes (Table 1) (8). ADARB2 (ADAR3) 
enzyme is considered catalytically inactive. Full length ADAR1p150 and amino terminal 
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truncated ADAR1p110 isoforms of ADAR are transcribed by alternative promoter usage. 
Except for ADARp150, an interferon-inducible isoform which can accumulate in the 
cytoplasm, all other ADARs are localized to the nucleus. ADARs catalyze site-specific 
RNA editing in short imperfect RNA duplexes, whereas hyperediting that involves many 
adenosines occurs in long perfect RNA duplexes. Majority of ADAR-mediated RNA 
editing events in long duplex RNAs occurs in the 3’-UTR and 5’-UTR of mRNAs and in 
introns, especially in the context of Alu sequences. Noncoding edited sites may play roles 
in the regulation of splicing, gene expression and miRNA binding (10).  In addition, 
RNA editing by ADAR recodes mRNAs of several genes including NEIL1 (11), BLCAP, 
FLNA (12) and NARF (13). 
 
Site-specific A>I RNA editing events that alter the amino acid code by missense 
substitutions occurs only in a handful of genes, which are often involved in 
neurotransmission in brain. For example, ADARB1 edits GluR-B mRNA leading to near 
100% change from the germ line encoded glutamine at amino acid 607 to arginine at the 
mRNA level. This change significantly alters the AMPA receptor neurotransmitter 
function. Loss of this editing in Adarb1-/- mice leads to lethal seizures shortly after birth 
(14). In contrast, loss of Adar gene leads to early embryonic lethality via defective 
hematopoietic stem cells, increased activation of interferon signaling and apoptosis (15), 
although the identity of the edited RNAs involved is unknown.   
 
Recently germ line mutations in ADAR were identified in the autoimmune disorder 
Aicardi-Goutières syndrome (AGS) (16).  ADAR mutations in AGS and Adar-/- mice 
upregulate interferon type I (IFN1) regulated genes. AGS is a genetically heterogeneous 
Mendelian disease caused by mutations in several genes involved in nucleic acid 
metabolism and is characterized by early onset progressive brain disease, certain skin 
lesions, glaucoma and, in some cases, features resembling systemic lupus erythematosus 
(17). Upregulation of IFN1 signaling pathway by ADAR mutations suggests that the 
editing activity of ADAR is required to block activation of innate immune signaling. It is 
thought that the lack of ADAR-mediated RNA editing in double stranded RNAs 
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stimulates cytosolic RNA sensing by MDA5-MAVS pathways, which are normally 
blocked by mismatched I-U base pairs (18, 19).   
 
 
RNA editing by APOBECs 
C>U RNA editing catalyzed by the APOBEC cytidine deaminases is significantly less 
common than A>I editing in baseline transcriptome sequencing studies. The prototype of 
cytidine deaminases that edit RNA is the APOBEC1 enzyme. APOBEC1 site-specifically 
edits mRNA of the APOB gene to introduce a premature stop codon enabling intestinal 
cells to produce a short protein isoform of Apo B (20).  Recent transcriptome sequencing 
studies identified additional RNA editing sites of APOBEC1, mostly in the 3’-UTRs (21, 
22).  APOBEC1 was the only C>U RNA editing enzyme known until the discovery of 
APOBEC3A (A3A) (23). A3A differs from other RNA editing enzymes in that its editing 
function is observed only after induction by certain stimulations in monocytes and 
macrophages or by exogenous overexpression in 293T cells (24).  Hypoxia (1% O2) or 
IFN1 in primary peripheral blood monocytes or IFN1 in monocyte-derived macrophages 
induce widespread site-specific RNA editing by A3A.  In monocytes, hypoxia and IFN1 
additively increases RNA editing levels which leads to recoding of over 80% of 
transcripts of certain genes. In contrast to ADARs, most RNA editing by A3A is highly 
site-specific and targets the coding regions of genes, often resulting in missense/nonsense 
alterations.  
  
Whether other APOBECs, including APOBEC2, A3B, A3C, A3DE, A3F, A3G, A3H and 
APOBEC4, also edit cellular RNAs under certain physiological circumstances is 
unknown. Although deamination of viral genetic materials or cancer genome by some 
APOBEC3s was observed (25), cytidine deaminase activity of these enzymes under non-
infectious, non-neoplastic physiological conditions has not yet been demonstrated. We 
recently described that transient overexpression of A3G in HEK293T cells also induces 
C>U RNA editing of distinct cellular transcripts (26). Although physiological function of 
RNA editing by A3A and A3G is unknown, the targeting of hundreds of cellular RNAs 
raises the possibility that aberrant activation of APOBECs, by overexpression, hypoxia or 
inhibition of mitochondrial respiration (27), may contribute to transcriptome-level 
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mutations in cancer cells. Since certain hypermutations in cancer genome have been 
attributed to A3A (28, 29), it is conceivable that A3A may also mediate RNA editing of 
cancer related genes. We have shown that overexpression of A3A in 293T cells causes 
missense mRNA alterations in tumor associated genes ATM, BARD1, BRCA1, BRCA2, 
BRIP1, MDM2, KMT2A, MSH2, PTEN, SF3B1 and TSC2 (24). The mechanism by which 
A3A is expressed in cancer cells to cause genome mutations is uncertain, since A3A 
expression is largely confined to myeloid cells. Perhaps, epigenetic alterations in cancer 
lead to aberrant expression of A3A. Alternatively, A3A RNA or protein may be 
physically transferred from myeloid cells to cancer cells through exosomes or by cell 
fusion (30). A3A-mediated RNA editing may also be induced in myeloid cells of tumor 
microenvironment (e.g. macrophages, myeloid derived suppressor cells) in hypoxic or 
inflammatory conditions, and affect tumor progression by altering the immunologic 
milieu (31). 
  
 
Altered RNA editing in cancer 
Recoding RNA editing in cancer 
RNA editing has been linked to tumorigenesis by either site-specific editing of tumor 
promoting genes or by transcriptome-scale changes in RNA editing levels. 
A>I RNA editing of AZIN1, which encodes an antizyme inhibitor, causes S367G amino 
acid substitution. RNA editing level of AZIN1 increases by at least 10% in hepatocellular 
carcinoma compared to normal unaffected liver (3). This editing generates an isoform 
with increased affinity to antizyme, promoting cell proliferation by reducing antizyme-
mediated degradation of ornithine decarboxylase and cyclin D1.  Site-specific A>I RNA 
editing of transcription factor PROX1 causes several missense alterations including 
E328G, R334G and H536R in a small number of esophageal, pancreatic and colon cancer 
samples, but no such editing is seen in a number of cDNA libraries of many normal 
tissues (32). By comparing the genome/transcriptome sequences, recoding A>I RNA 
editing, causing N136S amino acid change in RHOQ is found in colorectal cancer (33). 
This editing increases RhoQ GTPase enzyme activity, cancer invasion potential and 
recurrence of colorectal cancer when present in the tumor.  Increased recoding (M2269V) 
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RNA editing of filamin B gene (FLNB) is noted in hepatocellular (34) and esophageal 
squamous cell carcinomas (35). Increased recoding RNA editing of DNA repair enzyme 
NEIL1 (K242R) is identified in non-small-cell lung cancer samples as a result of ADAR 
gene amplification (36).  A rare example of C>U RNA editing in cancer involves the 
neurofibromatosis type I gene (NF1) mRNA editing that introduces a nonsense mutation 
in subset of peripheral nerve–sheath tumors (37-39). 
 
Reduced recoding RNA editing has also been observed in several tumors. For instance, 
RNA editing of GluR-B also causes R701G substitution in normal cerebellum and skin 
but it is markedly reduced in medulloblastoma cell lines and basal cell carcinoma 
samples (40). GluR-B Q607R editing is substantially lower in malignant gliomas which 
have reduced expression of the ADARB1 enzyme (41). In gastric cancer, oncogenic 
activity is promoted by the loss of ADARB1 which normally mediates recoding RNA 
editing H241R in PODXL to eliminate tumor promoting function of the wild type gene 
(42).  Chen et al (43) suggested that RNA editing enables proapoptotic function of 
IGFBP7, the loss of which may promote tumorigenesis in esophageal squamous cell 
carcinoma. The chloride receptor Gabra3 transcripts undergo recoding editing in the 
brain (44). Reduced RNA editing of GABRA3 in breast cancer is suggested to promote 
tumor progression, invasion and metastatic potential (45).  
 
Noncoding RNA editing in cancer 
Noncoding RNA editing is also suggested to promote tumorigenesis. In CD34+/CD117+ 
myeloblasts of acute myeloid leukemia, transcripts of PTPN6, which encodes SH2 
domain-containing tyrosine phosphatase, were found to retain an intron as a result of 
multiple A>I RNA editing events mainly at the intronic putative branch site (46). Such 
editing occurred at lower levels in remission blasts suggesting a link between editing and 
leukomogenesis. MicroRNAs are small noncoding RNAs that play an important role in 
post-transcriptional gene regulation by silencing gene expression. RNA editing of 
miRNAs can alter these regulatory functions of miRNAs.  Several studies have suggested 
that altered RNA editing of miRNAs or miRNA binding sites promote tumorigenesis. 
Increased ADAR-mediated RNA editing of stem cell regulatory let-7 micro-RNAs may 
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enhance leukemic self-renewal and contribute to blast crisis in CML (47).  In contrast, 
decreased RNA editing of miR-455-5p in melanoma enables downregulation of tumor 
suppressor CPEB1 and promotes tumor progression (48).  Increased RNA editing of 
miR-381, which is involved in stemness and chemoresistance is observed in non-small-
cell lung cancer (36).  Zhang et al (7) suggested that RNA editing at miRNA binding sites 
at 3’-UTR of gene transcripts may play an important role in suppressing the expression of 
tumor suppressor genes or increasing the expression of oncogenes. This study showed 
that increased RNA editing at miRNA binding sites at 3’-UTR of MDM2 increases the 
protein levels of MDM2 which is a negative regulator of p53 protein and is known to be 
elevated in many cancer types. 
  
Transcriptome scale analysis of RNA editing events in cancer 
Development of high throughput sequencing and analysis techniques has enabled 
researchers to analyze transcriptome-scale RNA editing events in cancer.  These studies 
reveal unanticipated heterogeneity of the cancer transcriptome, conferred largely due to 
A>I RNA editing. The first genome scale analysis of RNA editing in cancer examined 
sequences of expressed sequence tags in normal and neoplastic tissues, and found 
hypoediting of Alu repetitive elements in brain, prostate, lung, kidney, and testis tumors 
(49).  More recently, several groups examined the high throughput cancer RNA 
sequencing data, mostly from The Cancer Genome Atlas (TCGA) database, to determine 
the frequency of RNA editing in various neoplasms. Han et al (4) analyzed 17 cancer 
types and found abundant A>I editing, mostly in intronic, intergenic regions and in 3’-
UTR. They found increased global editing levels in breast tumors, as well as in head/neck 
squamous cell, thyroid, lung adenocarcinoma, bladder, kidney renal cell carcinomas. 
Decreased global editing levels were seen in kidney chromophobe, and renal papillary 
carcinoma. No difference in editing levels was seen in prostate, lung squamous, liver, 
stomach adenocarcinoma compared to the normal tissues. Interestingly, they found a 
positive correlation between global RNA editing levels with ADAR, but not with 
ADARB1/ADARB2 expression. In all tumors, editing levels in most sites were similar 
between normal control tissues and their cancer counterpart. For example, only 16.7% of 
all edited sites showed increased editing levels in BRCA and 19.3% of all edited sites 
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showed decreased levels in kidney chromophobe cell cancer. Only several dozen 
nonsynonymous editing sites were identified.  Correlations with one or more clinical 
outcomes (tumor subtype, stage and survival) were detected for S367G in AZIN1, I164V 
in COPA, I635V in COG3,  R764G in GRIA2, T262A in ACBD4, S59G in PPIL3, Q5R 
in BLCAP and H241R in PODXL. Edited gene variants in AZIN1, GRIA2 and COG3 
increased cell viability in MCF10A (normal human breast epithelium cell line) and Ba/F3 
(a murine leukemia cell line) cells.  
 
Paz-Yaacov (5) showed increased A>I RNA editing levels (>5%) in most cancer types, 
largely at Alu sites, but also at 60 recoding sites. Lower editing levels correlated with a 
better survival in hepatocellular and head/neck carcinoma cases.  Authors suggested that 
mutation load contributed by RNA editing may be more than those contributed by DNA 
mutations. Fumagalli et al (6) showed that the same sites are edited in primary breast 
cancer, normal breast tissue and breast cancer cell lines. However, higher frequency of 
editing is observed in tumor tissues as compared to normal and correlates positively with 
higher ADAR expression. Editing was mostly confined to Alu sites. 
 
Zhang et al (7) showed widespread A>I RNA editing events in cancer but they were not 
specific to a certain cancer type and were present in all tissues including normal controls. 
They identified 166 differentially edited genes between normal and tumor tissues. 
Smallest number (n=11) of differentially edited genes occurred in esophageal carcinoma, 
largest (n=62) in breast adenocarcinoma.  They confirmed increased editing levels of 
AZIN1 and decreased levels in IGFBP7 in most tumor types. The authors did not find a 
strong correlation between editing levels and ADAR expression levels, and suggested 
that RNA editing of 3’-UTR miRNA binding sites may strongly influence expression 
levels of tumor promoting or suppressor genes.   
 
Transcriptome sequencing studies in different cancer types are summarized in 
Supplementary Table 1. Although ADAR is the primary mediator of the A-to-I RNA 
editing events, there is no strong consensus on how to explain the editing efficacy of the 
events by correlation analysis against ADAR expression profiles.  RNA editing efficacy 
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is generally defined by the frequency of editing events or the extent of editing.  Several 
studies reported that frequency of editing events is correlated with ADAR expression 
levels (4), however, others also show that editing levels might not be directly associated 
with the ADAR expression profiles (7). This might suggest an alternative editing 
mediator (e.g. ADARB1) is activated to regulate the editing mechanism.  In general, 
majority of the events have low editing levels and consequently it is often difficult to 
make a confident estimation when the sequencing depth is low.  Increasing the 
sequencing depth might contribute to identifying the true positive hits and could improve 
the correlation of editing levels and ADAR expression profiles or better able to address 
the inconsistencies reported in the literature.  We obtained reported gene expression 
profiles based on RNA-sequencing for the cancer types with at least five normal samples, 
from The Cancer Genome Atlas (TCGA) project (https://portal.gdc.cancer.gov/). 
Comparing the distribution of expression levels for ADAR and ADARB1 between the 
tumor and normal samples for the selected cancers, fold change in their median 
expression levels and corresponding significance was calculated using Mann-Whitney U 
test (See Supplementary Table 1, Figure 1). Figure 1 organizes the cancer types based on 
reported editing levels in the literature (4-7, 42, 49, 50) for an easy comparison with the 
observed expression alterations for ADAR genes. Our analysis suggests that the increase 
in ADAR expression levels is correlated with the reported increases in editing levels in 
majority of the TCGA cancers. Extent of editing and ADAR expression levels are 
consistently increased in majority of the tumor types compared to the tissue matched 
normal samples, however, kidney cancers (i.e. Kidney Renal Clear Cell Carcinoma 
(KIRC), Kidney Renal Papillary Cell Carcinoma (KIRP) and Kidney Chromophobe 
(KICH)) exhibited low ADAR expression in agreement with the reported reduced editing 
levels (4, 5, 7). On the other hand, the change in ADARB1 expression did not appear to 
be associated with the corresponding reported changes in editing levels across cancers 
(See Figure 1). 
 
 
Summary and outlook 
Initial studies of RNA editing in cancer suggests that both genome and transcriptome 
sequencing studies are required to capture all sources of protein mutations in cancer. 
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Several patterns emerge from these initial studies. (a) Although RNA editing levels are 
altered in cancer, RNA editing does not appear to create new cancer-specific alterations 
since all sites edited in cancer are also edited in normal control tissues to some degree. 
Thus, cancer related changes in RNA editing appear to be in quantity rather than quality. 
(b) Most editing events detected to date occur in introns and 3’-UTRs. RNA editing in 
coding regions of genes are rare. (c) Tumor types show consistent patterns of increased or 
decreased RNA editing levels at the transcriptome scale. Despite these global patterns, 
editing levels change in the opposite direction at some edited sites in a given tumor type. 
For example, editing levels decrease in less than 10% of the edited sites in breast cancer, 
which overall show increased RNA editing levels. (d) Increase in editing levels in cancer 
often correlates with increased expression of the ADAR enzyme.   
 
In summary, recent studies have revealed abundant A>I RNA editing events in cancer 
which have been linked to tumor development through altered protein function caused by 
missense mutations, disrupted regulation by intronic or noncoding RNAs such as 
miRNAs and global or dynamic changes in RNA editing levels (Figure 2). Despite these 
promising data, how critical protein recoding RNA editing events are for the initiation 
and progression of cancer as well as the significance of vast number of non-coding RNA 
editing events in cancer remains uncertain. Recent studies linking ADAR-mediated RNA 
editing to suppression of IFN1 signaling raise the possibility that increased global A>I 
RNA editing observed in several cancers may serve to antagonize activation of IFN1 
responses which is known to be pro-apoptotic, anti-proliferative and anti-tumorigenic 
(51).  The lack of cancer specific RNA editing events starkly contrasts with numerous 
somatic DNA mutations in hundreds of genes identified in cancer, and raises the question 
as to why recoding RNA editing variants implicated in cancer (e.g. AZIN1) do not occur 
at the DNA level. Perhaps, mutations advantageous for cancer cell in most 
microenvironments are hardwired in the DNA, whereas those advantageous only in 
certain stage or changing environments may be regulated by RNA editing. Therefore the 
advantage of RNA editing for cancer cell may be in its dynamic nature. Consequently, 
RNA sequencing of cancer cells in different stages, histologic grades or micro-
environments may be required to identify the full compendium of fluctuating targets of 
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RNA editing. Such dynamic alterations may especially apply for C>U RNA editing by 
APOBEC3 enzymes since A3A-mediated RNA editing occurs only after hypoxia and/or 
IFN exposure.  RNA editing represents an exciting new frontier in cancer research with 
the potential to discover a rich source of epitranscriptomic mutations elusive to DNA 
sequencing.    
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Table 1 
RNA editing enzymes in humans 
 
Enzyme 
(editing 
activity) 
Function of RNA 
editing 
Cell type 
where RNA 
editing 
occurs 
Subcellular 
localization 
Recoding 
RNA editing 
targets 
ADAR  
(A>I) 
Suppression of 
innate immunity 
and protein 
diversification 
Many  Nuclear* Several (e.g. 
NEIL1) 
ADARB1 
(A>I) 
Protein 
diversification for 
normal neuronal 
signaling 
Many, but 
mostly CNS 
cells 
Nuclear Several 
dozens (e.g. 
GluR-B) 
ADARB2 
(A>I) 
Inactive (expressed 
in brain) 
None Nuclear Unknown 
APOBEC1 
(C>U) 
Apo B isoform 
(Apo B-48) 
production for 
absorption of 
dietary fat   
Intestine, 
liver 
Nuclear APOB 
APOBEC3A 
(C>U) 
Protein 
diversification for 
unknown function 
Monocytes 
and 
macrophages 
Nuclear/cytoplasm Hundreds to 
thousands 
APOBEC3G 
(C>U) 
Protein 
diversification for 
unknown function 
Unknown cytoplasm Hundreds 
 
*ADARp150 isoform is localized to cytoplasm.  
Legend for Figure 1 
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Histograms showing the fold change in median expression of ADAR and ADARB1 in a 
cancer type compared to normal samples. RNA-sequencing based gene expression 
profiles for ADARs were obtained for cancer types, with at least five normal samples 
from the same tissue, from the TCGA project (https://portal.gdc.cancer.gov/). Statistical 
significance was calculated using Mann-Whitney U-test comparing ADAR expression in 
normal and tumor samples (P-value; * <0.05, ** <0.01). Cancer types are organized 
based on reported editing levels in literature. Majority of the cancer types with increased 
extent of editing exhibited elevated ADAR1 expression in cancer compared to normal 
samples. Overedited sites outnumber underedited sites in kidney renal cell carcinoma 
(4,7), although global RNA editing levels are decreased (5). 
 
Legend for Figure 2 
Summary of various mechanisms through which RNA editing plays a role in the 
pathogenesis of cancer. (1) Increased or decreased recoding RNA editing can occur site-
specifically in oncogenes or tumor suppressor genes (3,32-29). (2) Increased or decreased 
RNA editing occurs in miRNA binding sites or miRNAs, resulting in increased or 
decreased expression of oncogenes or tumor suppressor genes, respectively (7,36, 46-48). 
(3) Increased global RNA editing occurs in the transcriptome resulting in suppression of 
the innate immune signaling (4-6). (4) APOBEC3 mediated RNA editing occurs 
dynamically (23) which might result in increased mutational load in cancer cells. 
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  Site-­‐specific	  recoding	  
A>I	  RNA	  editing
AZIN1 editing
Cell	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  pro-­‐apoptotic	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